• Users Online: 322
  • Print this page
  • Email this page
Year : 2017  |  Volume : 10  |  Issue : 4  |  Page : 213-226

Immunomodulatory treatments for relapsing–remitting multiple sclerosis

Department of Neurology, Medical University of Vienna, Vienna, Austria

Correspondence Address:
Fritz Leutmezer
Department of Neurology, Medical University of Vienna, Vienna
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7707/hmj.806

Rights and Permissions

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that encompasses both neuroinflammatory and prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and, until recently, licensed drugs could not satisfactorily halt this process. However, in recent years, MS treatment has entered a phase of rapid progress. Several new drugs with significantly improved efficacy have entered the therapeutic field, and several others are currently undergoing phase III clinical trials. In this review, the efficacy data and safety and tolerability issues of currently licensed drugs for relapsing–remitting MS will be summarized, including a short update on new drugs currently undergoing late-stage clinical trials.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal